Expect patent-heavy pharma acquisitions following Novartis’ $13 billion consumer healthcare divestment
Register to access two of our subscriber only articles per month.
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Author | Life sciences reporter
@IAM_magazine RT @IAM_magazine: It may not feel like it now, but once the Covid-19 crisis has passed (as it will), there are going to be very big opportu… Read more
@IAM_magazine It may not feel like it now, but once the Covid-19 crisis has passed (as it will), there are going to be very big o… https://t.co/zLTz9QOEkI Read more
@IAM_magazine Formula 1 safety tech at heart of new West Texas patent infringement suit https://t.co/tqU0mmDKio https://t.co/Jju3ewwHi7 Read more
@IAM_magazine RT @ktMINEglobal: The third annual IAM/ktMINE Patent 100 was featured in @IAM_magazine issue 99 - revealing a drop in applications. What do… Read more